Cleveland, Ohio (PRWEB) April 27, 2015
Diasome Pharmaceuticals, Inc. (“Diasome”) has announced the execution of an agreement with Joslin Diabetes Center (“Joslin”) to collaborate on the design of a Phase 2b study of Diasome’s novel Hepatocyte Directed Vesicle (“HDV”) targeting system for insulin in patients with Type 1 diabetes.
Located in Boston, Massachusetts, Joslin is the world's leading diabetes research, clinical care and education organization dedicated to the prevention, treatment and cure of diabetes. Joslin is an independent, non-profit institution affiliated with Harvard Medical School. Joslin conducts a wide range of clinical studies on new and approved treatments in both Type 1 and Type 2 patients and brings a wealth of expertise in directing new drugs and devices to improve patient outcomes. Diasome, founded in 2004, is a leading company focused on the development of novel therapies for treating metabolic diseases, including Type 1 and Type 2 diabetes. Its lead technology for hepatic targeted insulin has been enabled for Phase 3 testing by the US FDA.
”The Joslin Diabetes Center is focused on collaborating with pharmaceutical companies that are developing novel, cutting-edge therapies in the diabetes space. We are excited about helping with Diasome’s hepatic targeting concept and look forward to working with them,” said John L. Brooks III, President and CEO, Joslin Diabetes Center.
“The opportunity to work with the Joslin Diabetes Center on our novel diabetes technology is an important step in Diasome’s progress. Joslin is recognized around the world as the premier academic center for both the care of people with diabetes and research in Type 1 and Type 2 diabetes,” said W. Blair Geho, MD, PhD, Diasome’s Chief Scientific Officer and co-founder. “We very much appreciate the intellectual support and like-minded forward-thinking that the Joslin team brings to our planned study,” he said.
About Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.